NeuroSense Therapeutics CEO Provides Key Corporate Update Video

NeuroSense Therapeutics CEO Provides Key Corporate Update Video

CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/

-- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative

diseases, today released a video presentation with a corporate update from its Founder and CEO Alon Ben-Noon, View video here: https://youtu.be/MMXhD9DhPZg

Highlights of the presentation include the following:

Amyotrophic Lateral Sclerosis (ALS) Clinical

Program for Lead Drug Candidate PrimeC

- Pharmacokinetic study to be conducted under an FDA IND on track to be initiated in the coming weeks

- Phase IIb double-blind placebo controlled multinational study

Pipeline and IP Coverage

Tune into the video for more on NeuroSense's

progress to date and an overview of upcoming catalysts and milestones: https://youtu.be/MMXhD9DhPZg

NeuroSense Therapeutics, Ltd. is a clinical-stage

biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.

NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease,

among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available

for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of

related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to

Forward-Looking Statements

This press release contains "forward-looking

statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained

in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by

the use of words such as "anticipate," "believe," "contemplate," "could," "estimate,"

"expect," "intend," "seek," "may," "might," "plan," "potential,"

"predict," "project," "target," "aim," "should," "will" "would,"

or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking

statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions

that are difficult to predict and include statements regarding patent applications; the company's PrimeC development program; the potential

for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical

trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential

of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that

may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics

Ltd. undertakes no duty to update such information except as required under applicable law.

further information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183